Get the Stockscreener App
10.95
1.71%
-0.19
After Hours:
10.95
Immatics N V stock is traded at $10.95, with a volume of 628.78K.
It is down -1.71% in the last 24 hours and up +5.80% over the past month.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
See More
Previous Close:
$11.14
Open:
$11.2
24h Volume:
628.78K
Relative Volume:
1.44
Market Cap:
$1.47B
Revenue:
$53.99M
Net Income/Loss:
$-222.30M
P/E Ratio:
-6.0277
EPS:
-1.8166
Net Cash Flow:
$-213.50M
1W Performance:
-5.52%
1M Performance:
+5.80%
6M Performance:
+22.48%
1Y Performance:
+114.71%
1-Day Range:
$10.86
$11.53
1-Week Range:
$10.56
$11.65
52-Week Range:
$3.94
$12.41
Immatics N V Stock (IMTX) Company Profile
Compare IMTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMTX
Immatics N V
|
10.95 | 1.49B | 53.99M | -222.30M | -213.50M | -1.8166 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immatics N V Stock (IMTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Resumed | Jefferies | Buy |
| Sep-18-25 | Initiated | Guggenheim | Buy |
| May-28-25 | Initiated | Deutsche Bank | Buy |
| Oct-07-24 | Initiated | Piper Sandler | Overweight |
| Nov-02-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-31-23 | Initiated | Mizuho | Buy |
| Mar-24-23 | Initiated | Bryan Garnier | Buy |
| Nov-20-20 | Initiated | BofA Securities | Buy |
| Sep-22-20 | Initiated | Goldman | Buy |
| Jul-27-20 | Initiated | SVB Leerink | Outperform |
| Jul-24-20 | Initiated | Jefferies | Buy |
View All
Immatics N V Stock (IMTX) Latest News
Immatics (IMTX) to Release Quarterly Earnings on Tuesday - MarketBeat
TD Cowen initiates coverage of Immatics NV (IMTX) with buy recommendation - MSN
Immatics (NASDAQ:IMTX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Immatics NV Stock Operating Data - GuruFocus
Immatics NV (HAM:4A3) Cyclically Adjusted PS Ratio : (As of May. 01, 2026) - GuruFocus
Immatics NV (HAM:4A3) Stock News, Headlines & Updates - GuruFocus
Operating cash flow per share of Immatics N.V. – MUN:4A3 - TradingView
Net current asset value per share of Immatics N.V. – MUN:4A3 - TradingView
IMTX Initiates Coverage On TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Immatics stock coverage with buy rating By Investing.com - Investing.com India
TD Cowen initiates Immatics stock coverage with buy rating - Investing.com
(IMTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
IMTX: Jefferies Analyst Biren Amin Rates Immatics with a "Buy" and Sets Price Target at $18.00 | IMTX Stock News - GuruFocus
Immatics announces four oral presentations at ASCO meeting By Investing.com - Investing.com Australia
Immatics Secures Four High-Profile Oral Slots for PRAME and Bispecific Programs at 2026 ASCO - TipRanks
Immatics announces four oral presentations at ASCO meeting - Investing.com
Immatics (NASDAQ: IMTX) lines up four oral cancer therapy talks for ASCO 2026 - Stock Titan
Immatics Announces Four Upcoming Oral Presentations Across - GlobeNewswire
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting - ChartMill
Four cancer studies put Immatics’ cell therapies on ASCO stage - Stock Titan
Immatics NV stock (NL0015255052): Is its TCR-T cell platform strong enough to unlock biotech upside? - AD HOC NEWS
Immatics NV stock (NL0015255052): Is its TCR-T cell therapy platform strong enough to unlock biotech - AD HOC NEWS
Immatics (IMTX) Is Up 7.1% After Pediatric PRAME TCR Remission Case And AACR SpotlightHas The Bull Case Changed? - Sahm
Steffen Martin Walter Net Worth (2026) - GuruFocus
Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma - Sahm
Amie Elizabeth Krause Net Worth (2026) - GuruFocus
Immatics (IMTX) Showcases Pediatric Patient Breakthrough at AACR 2026 - GuruFocus
PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma - Investing News Network
Immatics Highlights PRAME-Targeted Cell Therapy Remission in Pediatric Kidney Cancer, Plans Pediatric Trial Expansion - TipRanks
Pediatric remission case for Immatics (NASDAQ: IMTX) PRAME cell therapy - Stock Titan
PRAME-directed Cell Therapy Using Immatics’ TCR Induces - GlobeNewswire
Jordan Zeik Silverstein Net Worth (2026) - GuruFocus
Cedrik Michael Britten Net Worth (2026) - GuruFocus
Sturchio Edward A Jr Net Worth (2026) - GuruFocus
Toni Michael Weinschenk Net Worth (2026) - GuruFocus
Reinhardt Carsten Alexander Johannes Net Worth (2026) - GuruFocus
Price-Driven Insight from (IMTX) for Rule-Based Strategy - Stock Traders Daily
ETF Watch: Can Immatics NV Equity Warrant generate free cash flow2026 Sentiment & Weekly Stock Breakout Alerts - baoquankhu1.vn
Exit Recap: Is Immatics NV currently under institutional pressure2026 Momentum & Capital Protection Trade Alerts - baoquankhu1.vn
Take Profit: Is Immatics NV forming a breakout pattern2026 News Drivers & Weekly High Conviction Ideas - baoquankhu1.vn
Risk Analysis: Should I invest in Immatics NV Equity Warrant before earningsEarnings Beat & Accurate Entry/Exit Alerts - baoquankhu1.vn
What do insiders think about Immatics N.V. (IMTX) Stock | Price at $10.32, Up 0.68%Trending Entry Points - Newser
(IMTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX - MarketBeat
IMTX Technical Analysis & Stock Price Forecast - Intellectia AI
Is Immatics (IMTX) Building a PRAME-Focused Platform or Stretching Its Oncology Ambitions Too Thin? - Sahm
IMTX Stock Analysis: Immatics N.V. Ordinary Shares rises 3.4 percent to 10.35 in biotech uptrend - Newser
What is the sentiment around Immatics N.V. (IMTX) Stock | Price at $10.35, Up 3.40%Retail Money Flow - Newser
Aug Technicals: Should I invest in Immatics NV Equity Warrant before earnings2026 PostEarnings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Retail Trends: Should you buy the dip on Immatics NV2026 Decliners & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Immatics N V Stock (IMTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):